explore -WSS

explore

author：knowledge 2025-09-29 19:04:57 - browse：55

In a lab at Harvard Medical School, Professor David A. Sinclair looks into the camera from behind a row of bottles — coverage from STAT — David Sinclair in his lab at Harvard Medical School. Craig F. Walker/Globe Staff

Renowned Harvard University geneticist and longevity researcher David Sinclair recently made an astonishing assertion: Scientists had developed the first pill — well, a soft, beef-flavored chew — “proven to reverse aging” in dogs. Which miracle molecules delivered this supposed scientific breakthrough, he didn’t say. But he told his 438,000 followers on X where they could buy it: the website of Animal Bioscience, a veterinary supplement company he founded and which is headed by his brother, Nick Sinclair.

The claim in a company news release, followed by the tweet stating that the supplement was “proven to slow the effects of aging,” has sparked outrage from other scientists online, and the board of an international organization of top longevity researchers — which David Sinclair leads — will discuss the matter at its meeting this week.

Despite his enthusiasm, there is no published scientific research that has yet demonstrated the compounds in Animal Bioscience’s supplements — which have been on the market for more than a year — reverse or even slow aging in dogs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Obamacare plans could cover weight loss drugs

hotspot

WSS

Cue Health, Covid

In 'major milestone,' FDA approves first cell therapy for solid tumors

MD Anderson's Padmanee Sharma responds to research credit suit

Secretariat’s lessons for human medicine

Digital health: a case of mistaken identity

Opioid cravings were reduced by anti

explore

explore

hotspot

Peter Hotez and the public health issue of online harassment

Surprise medical billing ban raises prices elsewhere

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

New air purifier tech could be key to improving indoor air quality

Flagship Pioneering startup Sonata Therapeutics lays off 21

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Opioid cravings were reduced by anti

leisure time

Hospitals are piloting generative AI tools as regulators play catch

Bird flu surveillance in wastewater gets boost from consortium

Biogen joins immunology wave with $1.15 billion acquisition of HI

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

New study raises questions about niacin and heart health

Bird flu surveillance in wastewater gets boost from consortium

focus

hotspot

focus

knowledge